Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gastrointestinal Cancers
How does your approach to contouring change when treating pancreatic body/tail lesions vs head tumors in the postop setting?
Answer from: Radiation Oncologist at Academic Institution
For tail lesions, we cover the splenic hilum and for head lesions, we cover the porta.
Sign in or Register to read more
11693
Related Questions
Would you consider proton therapy as part of TNT for rectal cancer?
When a patient with pancreatic cancer received neoadjuvant chemo + chemo-RT, how do you manage an in-field, post operative positive margin?
Which GI cancer patients do you use oral contrast in staging CT scans?
When treating pancreatic body/tail lesions that result in significant dose spread to the spleen, what is your threshold to offer pneumococcal, hemophilus influenza, and meningococcal vaccines?
Which patients, if any, treated according to PROSPECT for an early stage rectal cancer, would you offer surveillance if they achieved cCR after neoadjuvant chemotherapy?
How would you treat an MMR-proficient T2 N0 low-rectal cancer (measuring 2 cm extending 4-6 cm from the anal verge) in a patient who wishes to preserve his sphincter?
Would you offer liver re-irradiation in a Child-Pugh A patient with oligo-metastatic colon cancer to the liver, diagnosed > 10 years prior with previous TACE + SBRT to same liver metastasis ~5 years ago?
How likely is late radiation induced lumbosacral plexopathy from treatment of anal cancer with chemo-RT 20 years ago and how would you manage it?
When treating a high rectal cancer, does your coverage of the caudal mesorectum depend on the surgical plan?
Would you offer pelvic re-irradiation in the setting of locally recurrent anal cancer in the presacral region?